| Trial ID # | NCT03639246 |
| Phase | Ib/II |
| Drug Class | Growth Factor Inhibitors: Gas6 |
| Drug Name | Batiraxcept |
| Alternate Drug Names | anti-AXL fusion protein AVB-S6-500, AVB-S6-500, AVB-500 |
| Drugs in Trial | Batiraxcept, Liposomal doxorubicin, Paclitaxel |
| Eligible Participant | Platinum resistant ovarian cancer |
| Patients Enrolled | 53; AVB-S6-500+Pac: 23, median 2 prior therapies, 56% w/ prior Bev; AVB-S6-500+PLD: 30, median 1 prior therapy; 40% w/ prior Bev |
| Therapy Setting | Recurrence |
| Study Design | Double Blind, Randomized |
| Endpoints | ORR, DCR, PFS, evaluated per RECIST |
| Biomarkers | Exploratory: AVB-S6-500 levels in relation to minimal efficacious concentration (MEC) |
| Efficacy | RP2D for AVB-S6-500: 15 mg/kg Q2W (84% of patients achieves MEC) AVB-S6-500+Pac vs AVB-S6-500+PLD: Exploratory analysis, prior Bev, AVB-S6-500 serum trough levels, serum sAxl/Gas6 ratio: AVB-S6-500+Pac; PFI<3 months vs 3≤PFI<6 months: AVB-S6-500+Pac; trough levels above MEC vs below MEC: |
| Clinically Significant Adverse Events | AVB-S6-500+Pac vs AVB-S6-500+PLD: |
| Conclusion | AVB-S6-500+paclitaxel or liposomal doxorubicin is safe; the combination of AVB-S6-500+paclitaxel is most effective and best response is seen in patients without prior bevacizumab |
| Reference | Fuh KC et al. Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma. J Clin Oncol (2021) 39 (suppl 15; abstr 5566) Fuh KC et al. Poster Fuh KC et al. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecol Oncol (2021) 163(2):254-261 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.